http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3643713-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10a77948035833454698753b762d551a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15abfbaceca85b41d0d0f93b2bd5fb9e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63201f961f7f63e1a861755dfd917ede http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_302a8e2494b311b815b8ed393bba76cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a29f9610242f09c41efcacd366bd9c49 |
| publicationDate | 2020-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3643713-A1 |
| titleOfInvention | Heterocyclic kinase inhibitors and uses thereof |
| abstract | The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention can display one or more certain properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise one or more of the kinase inhibitors. The kinase inhibitors or pharmaceutical compositions of the invention may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. The kinase inhibitors or pharmaceutical compositions may be used in a treatment regimen that corresponds to, is similar to or is distinct from that used with dasatinib for a corresponding disorder, and in particular may be used in a combination treatment regimen together with one or more additional therapeutic agents, such as immune-checkpoint inhibitors. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021214117-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023067021-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3901151-A1 |
| priorityDate | 2018-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 561.